CHU de Limoges - Hôpital Dupuytren

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms	Embolism and Thrombosis, Hemic and Lymphatic Diseases, Hemorrhage, Myeloproliferative Disorders, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease, vascular disorder, venous thromboembolism	Recruiting	Phase 3	2026-03-20		NCT05198960
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder	Recruiting	Phase 3	2025-09-12		NCT03127267

Clinical trials